Clinical Guest Contributors

31. Researchers Want A Design Shake-Up In 2026 1/7/2026

    When asked what clinical research professionals should leave behind in 2025, quite a few lamented the stale, even problematic, approach to clinical trial design. Here's what they want done differently in 2026.

32. 2026: From Experimentation To Operational Reality In Clinical Research 1/6/2026

    Velocity Clinical Research COO Nick Spittal shares several trends he sees shaping up for 2026.

33. Sales & Operations Planning for Small Teams: Aligning Clinical Supply 1/6/2026

    Small clinical teams don’t fail at S&OP from missing systems—they fail from unclear demand and decisions. Alignment comes from discipline, shared visibility, and acting on reality before timelines slip.

34. How To Meet FDA Expectations For Hybrid And Decentralized Trial Oversight 1/5/2026

    Former FDA attorney Claire Davies shares strategies for meeting regulators' expectations for hybrid and decentralized clinical trial oversight.

35. No Surprise Here: Experts Value Clinical Relevance Over Statistical Relevance 12/31/2025

    Experts weighed in: “Agree or disagree? Statistical significance is preferable to clinical relevance.”

36. Trial Matching, Source Data, And More: How Clinical Researchers Used AI In 2025 12/30/2025

    Researchers reflect on the past year and share how they used AI for clinical research in 2025.

37. CRO Industry Outlook 2026: The Next Stage Of Clinical Trial Transformation 12/30/2025

    Beroe research manager Mathini Ilancheran reflects on the advances in AI, the rise of APAC as a global trial hub, new regulatory expectations, and increasing scientific complexity and forecasts how they will impact CROs in the coming year.

38. Mock Inspection Advice From Former Regulatory Investigator 12/30/2025

    Former FDA investigator Alia Legaux, D.H.Sc., runs through her top tips for running a mock investigation.

39. FDA Further Expands And Clarifies Expanded Access FAQs 12/29/2025

    Healthcare attorney Dianne J. Bourque breaks down the FDA's October 2025 update to its Expanded Access FAQs.

40. The Rise Of Antimicrobial Resistance And Strategic Research Imperatives For 2026 12/26/2025

    Antimicrobial resistance (AMR) has increasingly worried public health officials and researchers alike in 2025. Now, in 2026, TAXI Pharmaceutical President and CEO Gregory G. Mario, MBA, is calling for more targeted approaches and the integration of AI for quicker discovery and development.